Breast Cancer Clinical Trials in Chicago, Illinois

35 studies are recruiting for breast cancer in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

   The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Chicago Medical Center, Chicago, Illinois

   Locations

   53 in total

   Run by

   Jazz Pharmaceuticals

   See if you can join NCT07102381 on ClinicalTrials.gov

2. EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

   The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Rush Cancer Center, Chicago, Illinois

   Locations

   61 in total

   Run by

   Exact Sciences Corporation

   See if you can join NCT06401421 on ClinicalTrials.gov

3. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

   This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Illinois Cancer Center, Chicago, Illinois

   Locations

   96 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06172478 on ClinicalTrials.gov

4. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Illinois Cancer Center, Chicago, Illinois

   Locations

   26 in total

   Run by

   SystImmune Inc.

   See if you can join NCT06293898 on ClinicalTrials.gov

5. A Study of PHST001 in Advanced Solid Tumors

   This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advan…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago Medical Center, Chicago, Illinois

   Locations

   20 in total

   Run by

   Pheast Therapeutics

   See if you can join NCT06840886 on ClinicalTrials.gov

6. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

   This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Rush University Medical Center, Chicago, Illinois

   Locations

   243 in total

   Run by

   Relay Therapeutics, Inc.

   See if you can join NCT06982521 on ClinicalTrials.gov

7. Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment

   This study will be conducted in 2 sequential parts. The first part will be a prospective, observational study. This will be followed by a small interventional, pilot study involving use of fiber supplement (chia seeds). The study aims to evaluate the relationship between the gut microbiome (a diver…

   Stage

   Not phased

   Ages

   18 and older

   Site

   The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

   Run by

   University of Chicago

   See if you can join NCT07553234 on ClinicalTrials.gov

8. A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

   This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inop…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Chicago, Illinois

   Locations

   318 in total

   Run by

   AstraZeneca

   See if you can join NCT06103864 on ClinicalTrials.gov

9. Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

   Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BReast CAncer gene (BRCA) carriers) are recommended to have annual mammograms starting at age 40. Mammograms benefit women by detec…

   Stage

   Not phased

   Ages

   30 to 74

   Site

   University of Chicago, Chicago, Illinois

   Locations

   11 in total

   Run by

   University of California, San Francisco

   See if you can join NCT02620852 on ClinicalTrials.gov

10. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Northwestern Memorial Hospital, Chicago, Illinois

    Locations

    567 in total

    Run by

    Stemline Therapeutics, Inc.

    See if you can join NCT06492616 on ClinicalTrials.gov

11. Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

    Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, aromatase inhibitor alone or the combination of neratinib and an aromatase inhibitor. A breast biopsy will be performed prior to Day 1 of we…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Illinois Cancer Center, Chicago, Illinois

    Locations

    4 in total

    Run by

    Ruth O'Regan

    See if you can join NCT04886531 on ClinicalTrials.gov

12. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

    Stage

    Phase 3

    Ages

    18 to 60

    Site

    Mount Sinai Hospital Medical Center, Chicago, Illinois

    Locations

    1261 in total

    Run by

    NRG Oncology

    See if you can join NCT05879926 on ClinicalTrials.gov

13. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Northwestern University, Chicago, Illinois

    Locations

    79 in total

    Run by

    BriaCell Therapeutics Corporation

    See if you can join NCT06072612 on ClinicalTrials.gov

14. A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer

    This study is aimed to establish a registry of women undergoing intensive surveillance for the early detection of breast cancer in high-risk women.

    Stage

    Not phased

    Ages

    25 and older

    Site

    University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

    Locations

    3 in total

    Run by

    University of Chicago

    See if you can join NCT03729115 on ClinicalTrials.gov

15. TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

    The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HE…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Chicago Medical Center, Chicago, Illinois

    Locations

    11 in total

    Run by

    Ana C Garrido-Castro, MD

    See if you can join NCT06533826 on ClinicalTrials.gov

16. BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

    Adult men and women with early-stage, IHC/FISH-defined HER2-positive breast cancer will have a MammaPrint®/BluePrint® assay performed on the diagnostic biopsy specimen, ordered by the treating Oncologist as standard care

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Illinois, Chicago, Illinois

    Run by

    University of Illinois at Chicago

    See if you can join NCT06441890 on ClinicalTrials.gov

17. ATEMPT 2.0: Adjuvant T-DM1 vs TH

    This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    The University of Chicago Medical Center, Chicago, Illinois

    Locations

    53 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04893109 on ClinicalTrials.gov

18. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

    This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of car…

    Stage

    Phase 3

    Ages

    18 to 100

    Site

    Northwestern University - Northwestern Memorial Hospital, Chicago, Illinois

    Locations

    179 in total

    Run by

    Greenwich LifeSciences, Inc.

    See if you can join NCT05232916 on ClinicalTrials.gov

19. E-Mindfulness Approaches for Living After Breast Cancer

    NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants wi…

    Stage

    Phase 3

    Ages

    18 to 50

    Site

    Northwestern University, Chicago, Illinois

    Locations

    383 in total

    Run by

    NRG Oncology

    See if you can join NCT06748222 on ClinicalTrials.gov

20. Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)

    This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants will remain on combination abemaciclib + ET at the discretion o…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    University of Illinois, Chicago, Illinois

    Locations

    3 in total

    Run by

    University of Illinois at Chicago

    See if you can join NCT06169371 on ClinicalTrials.gov

21. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

    A Study of Emi-Le in Participants with Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Northwestern University, Chicago, Illinois

    Locations

    26 in total

    Run by

    Day One Biopharmaceuticals, Inc.

    See if you can join NCT05377996 on ClinicalTrials.gov

22. Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

    A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Northwestern University Robert H Lurie Medical Research, Chicago, Illinois

    Locations

    8 in total

    Run by

    Orano Med Theranostics, SAS

    See if you can join NCT05283330 on ClinicalTrials.gov

23. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic res…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Chicago, Chicago, Illinois

    Locations

    42 in total

    Run by

    QuantumLeap Healthcare Collaborative

    See if you can join NCT01042379 on ClinicalTrials.gov

24. Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

    This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Northwestern University, Chicago, Illinois

    Locations

    7 in total

    Run by

    Massachusetts General Hospital

    See if you can join NCT03990896 on ClinicalTrials.gov

25. Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

    The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: * Sacit…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Chicago Medical Center, Chicago, Illinois

    Locations

    7 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04434040 on ClinicalTrials.gov